Matches in Wikidata for { <http://www.wikidata.org/entity/Q37633475> ?p ?o ?g. }
- Q37633475 description "2016 nî lūn-bûn" @default.
- Q37633475 description "2016年の論文" @default.
- Q37633475 description "2016年学术文章" @default.
- Q37633475 description "2016年学术文章" @default.
- Q37633475 description "2016年学术文章" @default.
- Q37633475 description "2016年学术文章" @default.
- Q37633475 description "2016年学术文章" @default.
- Q37633475 description "2016年學術文章" @default.
- Q37633475 description "2016年學術文章" @default.
- Q37633475 description "2016年學術文章" @default.
- Q37633475 description "2016年學術文章" @default.
- Q37633475 description "2016年學術文章" @default.
- Q37633475 description "2016年學術文章" @default.
- Q37633475 description "2016년 논문" @default.
- Q37633475 description "article científic" @default.
- Q37633475 description "article scientific" @default.
- Q37633475 description "article scientifique publié en 2016" @default.
- Q37633475 description "articol științific" @default.
- Q37633475 description "articolo scientifico" @default.
- Q37633475 description "artigo científico (publicado na 2016)" @default.
- Q37633475 description "artigo científico (publicado na 2016)" @default.
- Q37633475 description "artigo científico" @default.
- Q37633475 description "artikull shkencor" @default.
- Q37633475 description "artikulong pang-agham" @default.
- Q37633475 description "artykuł naukowy" @default.
- Q37633475 description "artículo científico publicado en 2016" @default.
- Q37633475 description "artículu científicu espublizáu en 2016" @default.
- Q37633475 description "bilimsel makale" @default.
- Q37633475 description "bài báo khoa học" @default.
- Q37633475 description "mokslinis straipsnis" @default.
- Q37633475 description "naučni članak" @default.
- Q37633475 description "scienca artikolo" @default.
- Q37633475 description "scientific article published on 16 December 2016" @default.
- Q37633475 description "teaduslik artikkel" @default.
- Q37633475 description "tieteellinen artikkeli" @default.
- Q37633475 description "tudományos cikk" @default.
- Q37633475 description "vedecký článok" @default.
- Q37633475 description "vetenskaplig artikel" @default.
- Q37633475 description "videnskabelig artikel (udgivet 2016)" @default.
- Q37633475 description "vitenskapelig artikkel" @default.
- Q37633475 description "vitskapeleg artikkel" @default.
- Q37633475 description "vědecký článek" @default.
- Q37633475 description "wetenschappelijk artikel" @default.
- Q37633475 description "wissenschaftlicher Artikel" @default.
- Q37633475 description "επιστημονικό άρθρο" @default.
- Q37633475 description "мақолаи илмӣ" @default.
- Q37633475 description "мақолаи илмӣ" @default.
- Q37633475 description "наукова стаття, опублікована в грудні 2016" @default.
- Q37633475 description "научна статия" @default.
- Q37633475 description "научная статья" @default.
- Q37633475 description "научни чланак" @default.
- Q37633475 description "научни чланак" @default.
- Q37633475 description "գիտական հոդված" @default.
- Q37633475 description "מאמר מדעי" @default.
- Q37633475 description "سائنسی مضمون" @default.
- Q37633475 description "مقالة علمية نشرت في 16 ديسمبر 2016" @default.
- Q37633475 description "مقالهٔ علمی" @default.
- Q37633475 description "২০১৬-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ" @default.
- Q37633475 description "บทความทางวิทยาศาสตร์" @default.
- Q37633475 description "სამეცნიერო სტატია" @default.
- Q37633475 name "Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial" @default.
- Q37633475 name "Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial" @default.
- Q37633475 name "Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial." @default.
- Q37633475 type Item @default.
- Q37633475 label "Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial" @default.
- Q37633475 label "Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial" @default.
- Q37633475 label "Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial." @default.
- Q37633475 prefLabel "Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial" @default.
- Q37633475 prefLabel "Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial" @default.
- Q37633475 prefLabel "Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial." @default.
- Q37633475 P1433 Q37633475-6C014553-311E-4814-B945-6F30737D8137 @default.
- Q37633475 P1476 Q37633475-249E694C-E4A4-47DF-BD30-FAAAC98FF1AF @default.
- Q37633475 P2093 Q37633475-1B7A5A7F-DD27-4319-958B-42D4B833447A @default.
- Q37633475 P2093 Q37633475-2ED14C89-EF2F-414F-836D-01742B261778 @default.
- Q37633475 P2093 Q37633475-3522712A-199D-4CEE-8751-37785F0B9B80 @default.
- Q37633475 P2093 Q37633475-3D0177CE-E05E-4F80-8AE4-1564828E3C72 @default.
- Q37633475 P2093 Q37633475-53B8BC18-9E33-4FA5-819A-C6C890135AF9 @default.
- Q37633475 P2093 Q37633475-7061CBBC-7C92-4A10-9836-F00EB0CC734A @default.
- Q37633475 P2093 Q37633475-9088B1F6-F4BA-47DF-9010-8F71E80CE371 @default.
- Q37633475 P2093 Q37633475-91BF4F7B-37BB-4AE1-BD52-7A7E15F3A55E @default.
- Q37633475 P2093 Q37633475-A8C8650A-3E64-444E-866C-44C0E34240A7 @default.
- Q37633475 P2093 Q37633475-AE55E4B1-52E9-4957-87AE-527FD0D783D2 @default.
- Q37633475 P2093 Q37633475-CCED7072-71FB-4462-92AF-A39835383225 @default.
- Q37633475 P2093 Q37633475-E49E3731-5495-4E14-89EB-AB4DC632019B @default.
- Q37633475 P2093 Q37633475-E76ACC2C-BC70-4E18-8DED-E087A039070B @default.
- Q37633475 P2860 Q37633475-11B0D025-5AEE-48BF-A140-C88FDEAD2E3D @default.
- Q37633475 P2860 Q37633475-198461DC-A112-4534-97BD-ACCCDB72B175 @default.
- Q37633475 P2860 Q37633475-23AED927-7517-40C0-8A98-274744028089 @default.
- Q37633475 P2860 Q37633475-377236F3-38FD-4649-B184-19164DD94E6F @default.
- Q37633475 P2860 Q37633475-42D6C386-FF05-4DFE-A7D0-1C602869C50A @default.
- Q37633475 P2860 Q37633475-5A725F1A-63D6-4751-BAD4-7F594ADDEB73 @default.
- Q37633475 P2860 Q37633475-5D236434-B87D-4DAE-8224-4A763FAEAED9 @default.
- Q37633475 P2860 Q37633475-62F7C7ED-7538-4D84-8174-D6F057AE230C @default.
- Q37633475 P2860 Q37633475-670AEAE8-98C7-46C2-9E76-94312F4977DE @default.
- Q37633475 P2860 Q37633475-6FF4AB78-E805-46C8-A4D8-222A35FE3A89 @default.
- Q37633475 P2860 Q37633475-72A017EA-2258-4026-AE0C-0A1BAEB8B0E1 @default.
- Q37633475 P2860 Q37633475-88061226-855D-4A7E-9BFF-32861FFC8026 @default.
- Q37633475 P2860 Q37633475-8CC5FEA2-F809-4F8B-BAA9-6839737FE71C @default.
- Q37633475 P2860 Q37633475-B64D2020-5962-4720-9862-DC6DE2E50F6C @default.
- Q37633475 P2860 Q37633475-CA24FA7B-4620-4E2C-AF5F-3CBD03406A17 @default.